期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

依那西普联合阿维A治疗重症寻常型银屑病临床观察 被引量：7

下载PDF
导出
摘要 目的:观察依那西普联合阿维A治疗重症寻常型银屑病的临床疗效和安全性。方法:治疗组30例皮下注射依那西普联合口服阿维A,对照组31例仅口服阿维A。治疗12周后评价疗效。结果:治疗组有效率93.33%,对照组为64.52%,两组有效率差异有显著性。结论:依那西普联合阿维A治疗重症寻常型银屑病疗效明显。
作者 袁景奕 牛新武 闫小宁 肖生祥
机构地区 西安交通大学第二附属医院皮肤科 陕西省中医医院皮肤科
出处 《陕西医学杂志》 CAS 2010年第3期319-321,共3页 Shaanxi Medical Journal
关键词 银屑病/药物疗法 @依那西普 阿维A/治疗应用
分类号 R758.63 [医药卫生—皮肤病学与性病学]
  • 相关文献

参考文献10

  • 1Baker BS,Swain AF,Valdimarsson H.T cell subpopulation in the blood and skin of patients with psoriasis.Br J Dermatol,1984,110(1):37-44.
  • 2Katz HI,Waalen J,Leach EE.Acitretin in psoriasis:An overview ofadverse effects.J Am Acad Dermatol,1999,41 (3):7-12.
  • 3Cather J,Jennifer,Menter A,et al.Novel Therapies for Psoriasis.Am J Clin Dermatol,2002,3(3):159-173.
  • 4Arican O,Aral M,Sasmaz S,et al.Serum levels of TND-alpha,IFN-gamma,IL-6,IL-8,IL-12,IL-17,and IL-18 in patients with active psoriasis and clrrelation with disease severity.Mediators Inflamm,2005,(5):273-279.
  • 5Esposito M,Mazzotta A,de Felice C,et al.Treatment of erythrodermic psoriasis with etanercept.Br J Dermatol,2006,155(1):156-159.
  • 6Papp KA,Tyring S,Lahfa M,et al.A global phase III randomized controlled trial of etanercept in psoriasis:safety,efficacy,and effect of dose reduction.Br J Dermatol,2005,152 (6):1304-1312.
  • 7Katugampola RP,Lewis VJ,Finlay AY.The dermatology life quality index:assessing the efficacy of biological therapies for psoriasis.Br J Dermatol,2007,156(5):945-950.
  • 8Gottlieb AB,Leonardi CL,Goffe BS,et al.Etanercept monotherapy in patients with psoriasis:A summaty of safety,based on an integrated multistudy database.J Am Acad Dermatol,2006,54(3):92-100.
  • 9韩凌,方栩,黄琼,杨勤萍,傅雯雯,郑志忠,顾军,孙建方,许爱娥.注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白治疗中、重度寻常性银屑病疗效观察[J].临床皮肤科杂志,2007,36(11):730-732. 被引量：6
  • 10Symmons DP,Silman AJ.Anti-tumor necrosis factor alpha therapy and the risk of lymphoma in rheumatoid arthritis:no clear answer.Arthritis Rheum,2004,50:1703-1706.

二级参考文献7

  • 1Cather J, Menter A. Novel therapies for psoriasis[J]. Am J Clin Dermatol, 2002, 3(3): 159-173.
  • 2Esposito M, Mazzotta A, de Felice C, et al. Treatment of erythrodermic psoriasis with etanercept[J]. Br J Dermatol, 2006, 155 (1): 156-159.
  • 3Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis[J]. N Engl J Med, 2003, 349(21): 2014-2022.
  • 4Papp KA, Tyring S, Lahfa M, et al. A global phase Ⅲ randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction[J]. Br J Dermatol, 2005, 152(6): 1304-1312.
  • 5Chaudhari U, Romano P, Mulcahy LD, et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial[J], lancet, 2001, 357(9271): 1842-1847.
  • 6Mrowietz U, Zhu K, Christophers E. Treatment of severe psoriasis with anti-CD25 monoclonal antibodies [J]. Arch Dermatol, 2000, 136(5): 675-676.
  • 7Woolacott N, Hawkins N, Mason A. Etanercept and efalizumab for the treatment of psoriasis: a systematic review [J]. Health Technol Assess, 2006, 10(46): 251-252.

共引文献5

同被引文献69

  • 1Traczewski P,Rudnicka L.Treatment of systemic lupus erythematosus with epratuzumab.Br J Clin Pharmacol,2011,71(2):175-182.
  • 2Davis JC Jr,Totoritis MC,Rosenberg J,et al.Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131)in patients with systemic lupus erythematosus.J Rheumatol,2001,28(1):95-101.
  • 3Wolchok JD,Neyns B,Linette G,et al.Ipilimumab monotherapy in patients with pretreatod advanced melanoma:a randomised,double-blind,multicentre,phase 2,dose-ranging study.Lancet Oncol,2010,11(2):155-164.
  • 4Calero I,Sanz I.Targeting B cells for the treatment of SLE:the beginning of the end or the end of the beginning? Discov Med,2010,10(54):416424.
  • 5U.S.Food and Drug Administration (FDA).FDA approves Benlysta to treat lupus.March 9,2011.
  • 6Dillon SR,Harder B,Lewis KB,et al.B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoirmnune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin.ArthritisRes Ther,2010,12(2):R48.
  • 7Dall'Era M,Chakravarty E,Wallace D,et al.Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus:results of a multicenter,phase Ib,double-blind,placebo-controlled,dose-escalating trial.Arthritis Rheum,2007,56(12):4142-4150.
  • 8Lin WY,Gong Q,Seshasayee D,et at.Anti-BR3 antibodies:a new class of B-cell immunotherapy combining cdlular depletion and survival blockade.Blood,2007,110(12):3959-3967.
  • 9Dall'Era M,Wofsy D.Biologic therapy for systemic lupus erythematosus.Discov Med,2010,9(44):20-23.
  • 10Chan OC,Kaufman E,Daikh DI.CILA-4Ig substantially prolongs benefits of cyclophosphamide for lupus nephritis.Arthritis Rheum,2000,43:94.

引证文献7

二级引证文献27

陕西医学杂志
2010年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部